(Q46377533)

English

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

multiple sclerosis

0 references

author name string

James P Sheridan

1

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Ying Zhang

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Katherine Riester

3

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Meina T Tang

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Lyubov Efros

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Jia Shi

6

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Jeffrey Harris

7

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Vladimir Vexler

8

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Jacob S Elkins

9

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

publication date

1 August 2011

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

17

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

12

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

1441-1448

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Risk alleles for multiple sclerosis identified by a genomewide study

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Interleukin-2, interleukin-15, and their receptors

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo.

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells

1 reference

https://api.crossref.org/works/10.1177%2F1352458511414755

21 January 2018

Identifiers

10.1177/1352458511414755

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/21807759

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46377533&oldid=2108701391"